
Sai Life Sciences Limited has informed the Exchange regarding a press release dated January 28, 2026, titled "Strategic Collaboration Between Mabtech and Sai Life Sciences to Advance Immunology Research with EYRA Platform at Sai Boston Site.
Filed with NSE · · 3 pages · English
SAI Life Sciences Ltd. has announced a strategic collaboration with Mabtech to enhance immunology research at its Boston site, establishing it as a co-marketed hub for the Mabtech EYRA platform. This partnership aims to provide advanced immunology assay services, including multiplex cytokine workflows, to biopharma and biotech companies. The collaboration is designed to accelerate access to next-generation immune profiling capabilities in various therapeutic areas such as immuno-oncology and vaccines.
Written by 6ix AI from the company’s filing. How 6ix writes summaries

Sai Life Sciences Limited has informed the Exchange regarding a press release dated January 28, 2026, titled "Strategic Collaboration Between Mabtech and Sai Life Sciences to Advance Immunology Research with EYRA Platform at Sai Boston Site.
Follow SAI Life Sciences into a list and get an email when it puts out news.
Follow SAI Life Sciences